13-ID-197: A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio

Detalles del proyecto

EstadoFinalizado
Fecha de inicio/Fecha fin3/5/142/28/17

Financiación

  • PaxVax Incorporated: 159.327,00 US$